l General Information |
Product Name | Iniparib (BSI-201) |
General description | Iniparib is a small molecule iodobenzamide with potential cytotoxic and antineoplastic activities. |
Synonym | 4-iodo-3-nitrobenzamide; NSC-746045, IND-71677, BSI-201 |
Purity | ≥98.0%(HPLC) | CAS Number | 160003-66-7 |
Formula | C7H5IN2O3 | Molecular Weight | 292.03 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | ≥20mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Iniparib is a small molecule iodobenzamide with potential cytotoxic and antineoplastic activities. Although the mechanism of action is unknown, iniparib appears to be cytotoxic in cells with DNA alterations or DNA damage, like that found in tumor cells with mutations in the ataxia telangiectasia mutated (ATM) gene. ATM encodes a serine/threonine protein kinase and mutations of the gene are associated with ataxia telangiectasia and contribute to certain cancers such as T-cell acute
lymphoblastic leukemia, B-cell chronic lymphocytic leukemia and B-cell non-Hodgkin lymphomas. Iniparib is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). |
Application | Poly(ADP-ribose) Polymerase Inhibitors |
l Storage |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
